Jump to content

BMS-955176: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
No edit summary
 
(17 intermediate revisions by 15 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Infobox drug
{{Infobox drug
| drug_name =
| drug_name =
| INN =
| INN =
| type =<!-- empty -->
| type =<!-- empty -->
| IUPAC_name =
| IUPAC_name =
| image = BMS-955176.svg
| image = BMS-955176.svg
| alt =
| alt =
| caption =
| caption =
<!-- Clinical data -->
<!-- Clinical data -->
| pronounce =
| pronounce =
| tradename =
| tradename =
| Drugs.com =
| Drugs.com =
| MedlinePlus =
| MedlinePlus =
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment =
| pregnancy_AU_comment =
| pregnancy_US = <!-- A/B/C/D/X/N -->
| pregnancy_US = <!-- A/B/C/D/X/N -->
| pregnancy_category=
| pregnancy_category=
| routes_of_administration =
| routes_of_administration =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_AU_comment =
Line 27: Line 28:
| legal_status = Investigational
| legal_status = Investigational
<!-- Pharmacokinetic data -->
<!-- Pharmacokinetic data -->
| bioavailability =
| bioavailability =
| protein_bound =
| protein_bound =
| metabolism =
| metabolism =
| metabolites =
| metabolites =
| onset =
| onset =
| elimination_half-life =
| elimination_half-life =
| duration_of_action =
| duration_of_action =
| excretion =
| excretion =
<!-- Identifiers -->
<!-- Identifiers -->
| CAS_number =
| CAS_number = 1392312-45-6
| UNII_Ref = {{fdacite|correct|FDA}}
⚫
| ATCvet =
| UNII = 4CA9IAU7RJ
⚫
| ATCvet =
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix =
| ATC_suffix =
| PubChem =
| PubChem =
| DrugBank =
| ChemSpiderID = 58922159
| DrugBank =
<!-- Chemical data -->
<!-- Chemical data -->
| C=42|H=62|N=2|O=4|S=1
| C=42|H=62|N=2|O=4|S=1
| molecular_weight =
| molecular_weight =
| smiles = CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(CC=C(C5(C)C)c6ccc(cc6)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7
| StdInChI = 1S/C42H62N2O4S/c1-28(2)31-14-19-42(43-22-23-44-24-26-49(47,48)27-25-44)21-20-40(6)33(36(31)42)12-13-35-39(5)17-15-32(29-8-10-30(11-9-29)37(45)46)38(3,4)34(39)16-18-41(35,40)7/h8-11,15,31,33-36,43H,1,12-14,16-27H2,2-7H3,(H,45,46)/t31-,33+,34-,35+,36+,39-,40+,41+,42-/m0/s1
| StdInChIKey = XDMUFNNPLXHNKA-ZTESCHFWSA-N
}}
}}


'''BMS-955176''' is an experimental second generation [[HIV]] [[maturation inhibitor]] under [[drug development|development]] by [[Bristol-Myers Squibb]] for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.<ref>[http://www.aidsmeds.com/articles/BMS_maturation_inhibitor_1667_26859.shtml BMS Maturation Inhibitor Is Potent Against HIV in Early Trial]</ref> Because it targets a different step of the viral lifecycle than medications that are currently [[Food and Drug Administration|FDA]] approved, it offers promise for individuals with virus that has become highly resistant to other classes of [[HIV]] drugs.<ref>[http://www.businesswire.com/news/home/20150721006257/en/Second-Generation-Investigational-HIV-1-Maturation-Inhibitor-Demonstrates-Positive#.VbAEEhao53E Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development]</ref> First generation maturation inhibitors such as [[bevirimat]] were ineffective against some naturally occurring changes (polymorphisms) in the [[Gag protease]] polyprotein; BMS-955176 has been selected to better tolerate gag [[Polymorphism (biology)|polymorphisms]].<ref>[http://www.projectinform.org/hiv-news/croi2015-new-hiv-maturation-inhibitor-bms-955176-appears-more-potent-than-earlier-beviramat/ New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat]</ref><ref>{{Cite journal|title = Pharmacological intervention of HIV-1 maturation|url = http://www.sciencedirect.com/science/article/pii/S2211383515000787|journal = Acta Pharmaceutica Sinica B|date = 2015-11-01|pmc = 4675807|pmid = 26713265|pages = 493-499|volume = 5|issue = 6|doi = 10.1016/j.apsb.2015.05.004|first = Dan|last = Wang|first2 = Wuxun|last2 = Lu|first3 = Feng|last3 = Li}}</ref>
'''BMS-955176''' is an experimental second generation [[HIV]] [[maturation inhibitor]] under [[drug development|development]] by [[Bristol-Myers Squibb]] for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.<ref>{{cite web|url=http://www.aidsmeds.com/articles/BMS_maturation_inhibitor_1667_26859.shtml|title=BMS Maturation Inhibitor Is Potent Against HIV in Early Trial|date=25 February 2015|access-date=22 July 2015|archive-url=https://web.archive.org/web/20150723033900/http://www.aidsmeds.com/articles/BMS_maturation_inhibitor_1667_26859.shtml|archive-date=23 July 2015|url-status=dead}}</ref> First generation maturation inhibitors such as [[bevirimat]] were ineffective against some naturally occurring changes (polymorphisms) in the [[Gag protease]] polyprotein; BMS-955176 has been selected to better tolerate gag [[Polymorphism (biology)|polymorphisms]].<ref>{{cite web|url=http://www.projectinform.org/hiv-news/croi2015-new-hiv-maturation-inhibitor-bms-955176-appears-more-potent-than-earlier-beviramat/|title=CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform}}</ref><ref>{{cite journal | vauthors = Wang D, Lu W, Li F | title = Pharmacological intervention of HIV-1 maturation | journal = Acta Pharmaceutica Sinica B | volume = 5 | issue = 6 | pages = 493–9 | date = November 2015 | pmid = 26713265 | pmc = 4675807 | doi = 10.1016/j.apsb.2015.05.004 }}</ref>
__TOC__

== Studies ==
== Studies ==
Results of a [[Clinical trial|phase 2a]] trial of BMS-955176 was reported at the 2015 [[Conference on Retroviruses and Opportunistic Infections]] (CROI).<ref name=":0">{{Cite web|title = Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor {{!}} CROI Conference|url = http://www.croiconference.org/sessions/antiviral-activitysafety-second-generation-hiv-1-maturation-inhibitor|website = www.croiconference.org|accessdate = 2016-01-01}}</ref> Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.<ref name=":0" /><ref>{{Cite web|title = HIV maturation inhibitor BMS-955176 looks promising in early study|url = http://www.aidsmap.com/HIV-maturation-inhibitor-BMS-955176-looks-promising-in-early-study/page/2948854/|website = www.aidsmap.com|accessdate = 2016-01-01}}</ref> Phase 2b studies are currently ongoing in early 2016.<ref>{{Cite web|title = Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults - Full Text View - ClinicalTrials.gov|url = https://clinicaltrials.gov/ct2/show/NCT02415595|website = clinicaltrials.gov|accessdate = 2016-01-01}}</ref><ref>{{Cite web|title = Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults - Full Text View - ClinicalTrials.gov|url = https://clinicaltrials.gov/ct2/show/NCT02386098|website = clinicaltrials.gov|accessdate = 2016-01-01}}</ref> It appears that development of BMS-955176 has been terminated. <ref>http://www.thebodypro.com/content/78689/gsk-discontinues-development-of-maturation-inhibit.html</ref>
Results of a [[Clinical trial|phase 2a]] trial of BMS-955176 was reported at the 2015 [[Conference on Retroviruses and Opportunistic Infections]] (CROI).<ref name=":0">{{Cite web|title = Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor {{!}} CROI Conference|url = http://www.croiconference.org/sessions/antiviral-activitysafety-second-generation-hiv-1-maturation-inhibitor|website = www.croiconference.org|access-date = 2016-01-01}}</ref> Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.<ref name=":0" /><ref>{{Cite web|title = HIV maturation inhibitor BMS-955176 looks promising in early study|url = http://www.aidsmap.com/HIV-maturation-inhibitor-BMS-955176-looks-promising-in-early-study/page/2948854/|website = www.aidsmap.com|access-date = 2016-01-01}}</ref>

It appears that development of BMS-955176 has been terminated.<ref>{{cite web|url=http://www.thebodypro.com/content/78689/gsk-discontinues-development-of-maturation-inhibit.html|title=GSK Discontinues Development of Maturation Inhibitor BMS-955176}}</ref>

== See also ==
* [[Fipravirimat]]


==References==
== References ==
{{reflist}}
{{reflist}}


Line 59: Line 71:
[[Category:Antiretroviral drugs]]
[[Category:Antiretroviral drugs]]
[[Category:Maturation inhibitors]]
[[Category:Maturation inhibitors]]
[[Category:Experimental drugs]]
[[Category:Experimental antiviral drugs]]

Latest revision as of 20:41, 1 December 2023

BMS-955176
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC42H62N2O4S
Molar mass691.03 g·mol−1
3D model (JSmol)
  • CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(CC=C(C5(C)C)c6ccc(cc6)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7
  • InChI=1S/C42H62N2O4S/c1-28(2)31-14-19-42(43-22-23-44-24-26-49(47,48)27-25-44)21-20-40(6)33(36(31)42)12-13-35-39(5)17-15-32(29-8-10-30(11-9-29)37(45)46)38(3,4)34(39)16-18-41(35,40)7/h8-11,15,31,33-36,43H,1,12-14,16-27H2,2-7H3,(H,45,46)/t31-,33+,34-,35+,36+,39-,40+,41+,42-/m0/s1
  • Key:XDMUFNNPLXHNKA-ZTESCHFWSA-N

BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.[2][3]

Studies[edit]

Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.[4][5]

It appears that development of BMS-955176 has been terminated.[6]

See also[edit]

References[edit]

  1. ^ "BMS Maturation Inhibitor Is Potent Against HIV in Early Trial". 25 February 2015. Archived from the original on 23 July 2015. Retrieved 22 July 2015.
  2. ^ "CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform".
  3. ^ Wang D, Lu W, Li F (November 2015). "Pharmacological intervention of HIV-1 maturation". Acta Pharmaceutica Sinica B. 5 (6): 493–9. doi:10.1016/j.apsb.2015.05.004. PMC 4675807. PMID 26713265.
  4. ^ a b "Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor | CROI Conference". www.croiconference.org. Retrieved 2016-01-01.
  5. ^ "HIV maturation inhibitor BMS-955176 looks promising in early study". www.aidsmap.com. Retrieved 2016-01-01.
  6. ^ "GSK Discontinues Development of Maturation Inhibitor BMS-955176".
Retrieved from "https://en.wikipedia.org/w/index.php?title=BMS-955176&oldid=1187850095"